4/A: Arcellx Chief Medical Officer Reports Stock Transactions Following RSU Vesting
SEC Form 4/A Filing
Arcellx's Chief Medical Officer, Christopher Heery, executed multiple stock transactions, including the sale of shares to cover tax obligations related to vested restricted stock units.
Summary
- Christopher Heery, the Chief Medical Officer of Arcellx, Inc., reported changes in his beneficial ownership of company stock.
- On January 2, 2025, 13,021 restricted stock units (RSUs) vested, each representing one share of common stock.
- Following the vesting, Mr. Heery sold 2,975 shares on January 3, 2025, at a weighted average price of $79.5481 per share.
- He sold an additional 2,975 shares on January 6, 2025, at a weighted average price of $77.1668 per share.
- These sales were conducted to cover tax withholding obligations associated with the vesting of the RSUs.
- After these transactions, Mr. Heery directly owns 32,868 shares of Arcellx common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It does not contain any information that would be considered positive or negative from an investment perspective.
Industry Context
This is a routine filing related to stock transactions by a company insider, which is common practice in publicly traded companies. It does not indicate any specific trend or event within the biotechnology industry.
Comparison to Industry Standards
- Stock transactions by company executives are a standard practice across all industries, including biotechnology.
- The sale of shares to cover tax obligations related to vesting RSUs is a common occurrence.
- The reported transactions are consistent with standard reporting requirements for insider trading.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are routine and related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/02/2024 | RSU Grant Date |
| 01/02/2025 | Restricted stock units vested |
| 01/03/2025 | Sale of 2,975 shares |
| 01/06/2025 | Sale of 2,975 shares and original Form 4 filing date |
| 01/10/2025 | Date of amended filing |
Keywords
Arcellx, stock transactions, restricted stock units, RSU, insider trading, beneficial ownership, tax withholding, Christopher Heery, chief medical officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.